RESUMEN
PURPOSE: To evaluate the microvasculature during remission in patients with pars planitis (PP-IU) and multiple sclerosis-associated intermediate uveitis (MS-IU) using optical coherence tomography angiography (OCT-A). METHODS: Single-center, descriptive, case-control study was conducted. Adult patients (≥16 years) with IU in remission (PP-IU and MS-IU) and healthy age-sex matched healthy controls (HC) were enrolled to the study. Demographic/clinical features, best-corrected visual acuity (BCVA), ocular findings, neurological symptoms and preferred treatments were recorded. The presence of cystoid macular edema (CME) during follow-up was recorded. All IU patients in remission and HC subjects were scanned with OCT-A. Foveal avascular zone (FAZ) areas of superficial and deep capillary plexus (SCP/DCP) and vascular densities of SCP, DCP and choriocapillaris were obtained from OCT-A and compared between the groups. RESULTS: Sixty-nine eyes of 37 IU patients in remission and 20 HC were included (44 eyes/23 patients in PP-IU, 25/14 in MS-IU, 40/20 in HC). No statistically significant differences were observed in terms of demographic or clinical characteristics of the patients. The vascular density in the SCP was significantly reduced in the PP-IU and MS-IU groups compared to the HC group (p < .05). Nevertheless, there were no significant changes in any of the OCTA parameters between the IU groups. Uveitis duration was found to be correlated with enlargement of the FAZ area in PP-IU (p = .039). CONCLUSION: OCTA may not be useful in differentiating between PP-IU and MS-IU. Nevertheless, the primary implication in SCP potentially elucidates the pathogenesis of these two subtypes of IU, which are characterized by a shared pathogenesis. The monitoring of the FAZ area in the PP-IU group is valuable in terms of chronicity.
Asunto(s)
Angiografía con Fluoresceína , Esclerosis Múltiple , Pars Planitis , Vasos Retinianos , Tomografía de Coherencia Óptica , Uveítis Intermedia , Agudeza Visual , Humanos , Tomografía de Coherencia Óptica/métodos , Masculino , Femenino , Adulto , Uveítis Intermedia/diagnóstico , Uveítis Intermedia/fisiopatología , Uveítis Intermedia/tratamiento farmacológico , Angiografía con Fluoresceína/métodos , Agudeza Visual/fisiología , Esclerosis Múltiple/diagnóstico , Esclerosis Múltiple/complicaciones , Esclerosis Múltiple/diagnóstico por imagen , Vasos Retinianos/patología , Vasos Retinianos/diagnóstico por imagen , Pars Planitis/diagnóstico , Adulto Joven , Persona de Mediana Edad , Estudios de Seguimiento , Estudios de Casos y Controles , Fondo de Ojo , AdolescenteRESUMEN
PURPOSE: To report the clinical and fluorescein angiographic (FA) features of demyelinating plaque-associated uveitis (DPU), a subset of uveitis in which patients have demyelinating plaques on the brain/cervical magnetic resonance image (MRI) but do not meet the criteria for multiple sclerosis (MS). METHODS: In this retrospective observational study, Persian Patients were diagnosed with DPU and included if (1) they never satisfied the MS criteria, (2) all other possible etiologies were excluded, and (3) they were followed for at least 2 years. RESULTS: After a median follow-up of 3 years (interquartile range, 2.0-5.3), 8 out of 40 (20%) patients diagnosed with DPU were excluded as they subsequently met the MS criteria. Of remaining 32 patients studied, the mean age was 36.3±9.9 (range 20-56 years), and 30 (93.8%) were female. Twenty-four (75.0%) showed bilateral involvement and 27 (84.4%) had insidious-chronic course. Uveitis was classified as intermediate (with or without anterior uveitis) in 29 (90.6%) and isolated anterior in 3 (9.4%) patients. Nine (28.1%) patients had at least one systemic neurological complaint. Ocular findings were: granulomatous keratic precipitates in 43/44 (97.7%) eyes; snowballs in 25/52 (48.1%) eyes; snowbanks in 4/52 (7.7%) eyes; cystoid macular edema in 20/56 (35.7%) eyes; and optic neuritis in 5/56 (8.9%) eyes. Visual acuity was ≥ 20/40 in 39 eyes (69.6%) at presentation which improved to 46 eyes (81.2%) at 2-year follow up. The two most frequent findings in FA were optic disc leakage/staining in 44/52 (81.5%) eyes, and peripheral retinal perivascular leakage in 39/52 (76.9%) eyes, which in 14/52 (26.9%) eyes extended beyond the equator. CONCLUSION: DPU usually presents as a bilateral chronic granulomatous intermediate and, less often, isolated anterior uveitis, especially in females. Most are neurologically asymptomatic. Visual outcome is generally favorable. In FA, peripheral retinal perivascular leakage is common. DPU patients have an increased tendency to develop MS and should be prohibited from anti-TNF treatment.
Asunto(s)
Placa Aterosclerótica , Uveítis Anterior , Uveítis Intermedia , Uveítis , Humanos , Femenino , Adulto Joven , Adulto , Persona de Mediana Edad , Masculino , Inhibidores del Factor de Necrosis Tumoral/uso terapéutico , Uveítis/diagnóstico , Uveítis Anterior/diagnóstico , Uveítis Anterior/tratamiento farmacológico , Uveítis Anterior/etiología , Retina , Angiografía con Fluoresceína , Estudios Retrospectivos , Uveítis Intermedia/diagnóstico , Uveítis Intermedia/tratamiento farmacológicoRESUMEN
We review patient-reported outcome measures (PROMs) used to evaluate the quality of life (QoL) in uveitis and provide a quality assessment of the psychometric properties of the PROMs, making it easier to choose the best questionnaire for uveitis. Our review included 158 articles. A total of 98 PROMs were used to measure QoL in uveitis and the National Eye Institute Visual Function Questionnaire 25 (NEI VFQ -25) was the most frequently used PROM in these studies. There were 5 uveitis-specific PROMs, but they were meant for either birdshot choroidopathy or cytomegalovirus retinitis or paediatric uveitis. There are no PROMs developed explicitly for the more common, anterior uveitis, intermediate uveitis, panuveitis, and chronic uveitis. The uveitis-specific PROMs performed better in our quality assessment criteria compared to other PROMs. However, these PROMs were constructed using traditional classical test theory and have not been assessed using the modern family of psychometric assessment methods such as Rasch analysis. As new therapeutic modalities for uveitis such as the new biological agents and steroid implants, continue to evolve, a comprehensive PROM will be increasingly valued in clinical trial settings to compare the effects of treatments from the patient's perspective.
Asunto(s)
Uveítis Intermedia , Uveítis , Humanos , Niño , Calidad de Vida , Uveítis Intermedia/tratamiento farmacológico , Visión Ocular , Encuestas y Cuestionarios , Medición de Resultados Informados por el PacienteRESUMEN
PURPOSE: This review aims to provide an update on the clinical presentation, etiologies, complications, and treatment options in intermediate uveitis (IU). METHODS: Narrative literature review. RESULTS: IU affects all age groups with no clear gender predominance and has varied etiologies including systemic illnesses and infectious diseases, or pars planitis. In some instances, IU may be the sole presentation of an underlying associated condition or disease. Management of IU and its complications include administration of corticosteroids, antimetabolites, T-cell inhibitors, and/or biologics, along with surgical interventions, with varying degrees of effectiveness across literature. In particular, increasing evidence of the safety and efficacy of immunomodulatory agents and biologics has seen greater adoption of these therapies in clinical practice. CONCLUSIONS: IU is an anatomical description of uveitis, involving intraocular inflammation of the vitreous, peripheral retinal vasculature, and pars plana. Various treatment options for intermediate uveitis are currently used in practice.
Asunto(s)
Pars Planitis , Uveítis Intermedia , Uveítis , Humanos , Uveítis Intermedia/diagnóstico , Uveítis Intermedia/tratamiento farmacológico , Uveítis Intermedia/complicaciones , Pars Planitis/complicaciones , Uveítis/diagnóstico , Uveítis/tratamiento farmacológico , Trastornos de la Visión , Linfocitos TRESUMEN
PURPOSE: To report a case of multiple sclerosis (MS) development in a patient with Juvenile Idiopathic Arthritis (JIA) and bilateral intermediate uveitis (IU) treated with Adalimumab. CASE REPORT: A 21-year-old Colombian woman diagnosed with JIA and bilateral refractory IU treated with methotrexate and Adalimumab with difficult control of the disease and multiple ocular complications. Eight years after starting Adalimumab, the patient presented paresthesia in the left upper limb. Radiologic findings in the brain and cervical spine MRI confirmed the diagnosis of MS. CONCLUSIONS: We reported the first case of MS development in a patient with JIA treated with Adalimumab and the third in a patient with noninfectious uveitis treated with anti-TNFα. It remains uncertain whether MS is secondary to anti-TNFα therapy or is linked to a polyautoimmunity phenomenon.
Asunto(s)
Antirreumáticos , Artritis Juvenil , Esclerosis Múltiple , Uveítis Intermedia , Uveítis , Femenino , Humanos , Adulto Joven , Adulto , Adalimumab/efectos adversos , Artritis Juvenil/complicaciones , Artritis Juvenil/diagnóstico , Artritis Juvenil/tratamiento farmacológico , Antirreumáticos/efectos adversos , Esclerosis Múltiple/tratamiento farmacológico , Uveítis/diagnóstico , Uveítis/tratamiento farmacológico , Uveítis/etiología , Uveítis Intermedia/complicaciones , Uveítis Intermedia/diagnóstico , Uveítis Intermedia/tratamiento farmacológicoRESUMEN
PURPOSE: To report the predictive clinical factors for abnormal magnetic resonance imaging (MRI) scans suggestive of demyelination by analysis of MRI's performed for adult non-infectious uveitic patients prior to commencing adalimumab therapy. METHODS: Retrospective case review of 240 patients was conducted in a single tertiary institution between November 2017 and March 2020. Aetiology of underlying disease, clinical characteristics, and MRI outcomes were analysed. RESULTS: The presence of bilateral idiopathic intermediate uveitis (IIU) (p = .0048) and neurological symptoms (p = .028) were highly predictive of an abnormal MRI strongly suggestive of demyelination (MRSSD); 5 out of 64 scans (7.8%) with these clinical characteristics had MRSSD. CONCLUSIONS: Tumor necrosis factor antagonist-induced demyelination is a concern in adalimumab use. We propose an MRI screening protocol to identify those at high risk of demyelination; positive results can be maximised by screening all patients with IIU and those with neurological symptoms.
Asunto(s)
Enfermedades Desmielinizantes , Uveítis Intermedia , Uveítis , Humanos , Adulto , Adalimumab/efectos adversos , Estudios Retrospectivos , Uveítis/diagnóstico , Uveítis/tratamiento farmacológico , Uveítis/etiología , Uveítis Intermedia/tratamiento farmacológico , Enfermedades Desmielinizantes/complicaciones , Enfermedades Desmielinizantes/tratamiento farmacológico , Imagen por Resonancia Magnética , Factor de Necrosis Tumoral alfa/uso terapéutico , Resultado del TratamientoRESUMEN
INTRODUCTION: Belatacept is associated with a higher incidence of cytomegalovirus (CMV) disease and atypical presentations. Ocular manifestations are rare, representing up to 5% of disease manifestations and previous cases consisted in isolated retinitis. CASE DESCRIPTION: Herein, we report the case of an 81-year-old kidney transplant recipient who developed an anterior and intermediate uveitis under belatacept therapy. The diagnosis was established using quantitative CMV polymerase chain reaction assays in the aqueous humor. Belatacept was interrupted and oral and topical valganciclovir treatments were instituted. Lesions however extended, leading to intensify the treatment by intra-venous and intra-vitreal ganciclovir injections. Visual acuity stabilized and ocular inflammation was finally controlled after 3 months. CONCLUSION: Clinicians should be aware of CMV infection as a cause of anterior uveitis under belatacept-based regimen, even in the absence of symptoms suggestive of systemic CMV replication.
Asunto(s)
Infecciones por Citomegalovirus , Trasplante de Riñón , Uveítis Anterior , Uveítis Intermedia , Humanos , Anciano de 80 o más Años , Antivirales/uso terapéutico , Abatacept/uso terapéutico , Trasplante de Riñón/efectos adversos , Ganciclovir/uso terapéutico , Infecciones por Citomegalovirus/diagnóstico , Infecciones por Citomegalovirus/tratamiento farmacológico , Uveítis Anterior/diagnóstico , Uveítis Anterior/tratamiento farmacológico , Uveítis Intermedia/tratamiento farmacológicoRESUMEN
AIM: To study the long-term efficacy and safety of Ozurdex as anti-inflammatory monotherapy in the management of tuberculosis-associated intermediate uveitis (TBIU). METHODS: Retrospective analysis of eyes with TBIU that received Ozurdex as anti-inflammatory monotherapy with a follow-up of at least 1 year. RESULTS: 13 eyes (2 pseudophakic) of 11 patients were included. Mean BCVA improved from 0.65 to 0.11 at 3 months (p = .0005) and remained 0.11 at 1 year. Mean central foveal thickness improved from 452.87µ to 187.25µ at 3 months (p = .0009) and 184.62µ at 1 year in 8 eyes with CME. Mean vitreous haze improved from 2.38 to 0.11 at 3 months with no recurrences at 1 year. Mean IOP increased from 13.15mmHg to 15.53mmHg (p = .013) at 2 months and reduced to 12.46mmHg by 1 year. None required antiglaucoma medication. One eye underwent cataract surgery. The mean follow-up was 18.4 months. CONCLUSION: Ozurdex is safe and efficacious in TBIU as anti-inflammatory monotherapy in conjunction with antitubercular therapy.
Asunto(s)
Edema Macular , Tuberculosis , Uveítis Intermedia , Uveítis , Humanos , Glucocorticoides/uso terapéutico , Estudios Retrospectivos , Edema Macular/tratamiento farmacológico , Implantes de Medicamentos , Antiinflamatorios/uso terapéutico , Dexametasona , Inyecciones Intravítreas , Uveítis Intermedia/complicaciones , Uveítis Intermedia/diagnóstico , Uveítis Intermedia/tratamiento farmacológico , Uveítis/complicaciones , Uveítis/diagnóstico , Uveítis/tratamiento farmacológicoRESUMEN
Purpose: To report the prevalence, clinical profile, investigations, and visual outcomes of sarcoid intermediate uveitis in a tertiary eye care center in South India. Methods: Retrospective, observational case series. Records of 29 patients with sarcoid intermediate uveitis were retrieved. Complete ophthalmic evaluation and systemic examination by a pulmonologist with appropriate laboratory investigations were done. Results were analyzed using SPSS software. Results: Mean age group was 42.14 ± 11.31 years. The bilateral presentation was more common and females were more affected than males. Anterior chamber cells and flares in 22.4% of cases (N = 11 eyes), posterior synechiae in 20.4% (N = 10 eyes), and both small and mutton fat keratic precipitates in 14.2% of cases (N = 7 eyes) were noted; only one eye had Busacca nodules similar to other granulomatous uveitis. Cystoid macular edemas were present in three eyes. Treatment with oral steroids and systemic immunosuppression resulted in good visual recovery. The mean presenting visual acuity in right and left eye were 0.2 and 0.3, respectively. The mean final visual acuity in right and left eye was 0.1 and 0.3, respectively. Conclusion: Sarcoid intermediate uveitis is quite common in a tuberculosis endemic country like India. A complete review of systems with appropriate investigations is essential to prevent visual complications.
Asunto(s)
Anomalías del Ojo , Sarcoidosis , Uveítis Intermedia , Uveítis , Adulto , Anomalías del Ojo/complicaciones , Femenino , Humanos , India/epidemiología , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Retrospectivos , Sarcoidosis/complicaciones , Sarcoidosis/diagnóstico , Sarcoidosis/epidemiología , Uveítis/diagnóstico , Uveítis/tratamiento farmacológico , Uveítis/epidemiología , Uveítis Intermedia/diagnóstico , Uveítis Intermedia/tratamiento farmacológico , Uveítis Intermedia/epidemiologíaAsunto(s)
COVID-19/complicaciones , Síndrome de Respuesta Inflamatoria Sistémica/complicaciones , Uveítis Intermedia/etiología , Adolescente , COVID-19/diagnóstico , COVID-19/terapia , Dexametasona/uso terapéutico , Humanos , Masculino , SARS-CoV-2/aislamiento & purificación , Síndrome de Respuesta Inflamatoria Sistémica/diagnóstico , Síndrome de Respuesta Inflamatoria Sistémica/terapia , Resultado del Tratamiento , Uveítis Intermedia/diagnóstico , Uveítis Intermedia/tratamiento farmacológicoRESUMEN
PURPOSE: To describe the course of childhood-onset intermediate uveitis without associated systemic disease, and investigate determinants of outcomes. DESIGN: A retrospective clinical cohort study METHODS: This study was conducted in an institutional setting. A total of 125 children (221 eyes) aged 16 years and less participated. Outcomes of interest were visual acuity, severity of inflammation, and the occurrence of sight-threatening complications. Variables examined included age and clinical findings at presentation, treatment, and duration of follow-up. Multivariable analysis was undertaken to investigate potential predictors of outcomes. RESULTS: The median follow-up duration was 57 months. At presentation, best-corrected visual acuity worse than 20/160 was recorded in 11 (4.4%) eyes and significant vitreous haze (≥2+Standardisation of Uveitis Nomenclature (SUN)) in 35 (14%) eyes. Corticosteroid-sparing agents were used in 41 children (33%), with methotrexate most commonly used (27 children, 21.6%). The most frequent complications were raised intraocular pressure (n = 65; 29.4%), cataract (n = 41; 18.5%), and cystoid macular edema (n = 29; 13.1%). At the last visit, 116 (92.8%) patients achieved best-corrected vision of 20/40 or better with quiescent uveitis. The absence of the use of a steroid-sparing immunomodulatory agent was the strongest predictive factor for the development of new macular edema (odds ratio = 6.3, 95% CI = 2.3-16.9, P < .001) or glaucoma (odds ratio = 6.6, 95% CI = 2.5-17.9, P < .001) over the period of observation. CONCLUSIONS: The visual outcomes of childhood-onset idiopathic intermediate uveitis are favorable. The frequency of sight-threatening sequelae of inflammation, which confer a lifelong risk of further visual loss, is high. The use of immunomodulatory therapy is associated with a lower risk of developing macular edema and ocular hypertension.
Asunto(s)
Glaucoma , Edema Macular , Uveítis Intermedia , Uveítis , Niño , Glaucoma/complicaciones , Humanos , Inflamación/complicaciones , Edema Macular/tratamiento farmacológico , Estudios Retrospectivos , Uveítis/complicaciones , Uveítis/diagnóstico , Uveítis/tratamiento farmacológico , Uveítis Intermedia/complicaciones , Uveítis Intermedia/diagnóstico , Uveítis Intermedia/tratamiento farmacológicoRESUMEN
PURPOSE: To evaluate the efficacy of Ozurdex implant by analyzing macular morphology and function in pediatric uveitis and related cystoid macular edema (CMO). METHODS: Main outcomes were visual acuity, mfERG and photopic ERG response, and central macular thickness. Mean values recorded at each time-point were compared to baseline and correlations between functional and anatomical parameters were evaluated. RESULTS: Resolution of intraocular inflammation and CMO was achieved in all eyes 1 month after implant without procedure or drug-related complications. Mean visual acuity and mfERG amplitude improved showing a statistically significant difference to baseline values for the first 4 months. Mean central macular thickness showed a statistically significant reduction for all follow-up time. Photopic ERG did not vary significantly. Statistically significant correlation was found between trends of visual acuity, central macular thickness, and mfERG responses. CONCLUSION: Correlation found between macular morphology and function confirms the efficacy of Ozurdex in pediatric uveitis.
Asunto(s)
Edema Macular , Uveítis Intermedia , Uveítis , Niño , Dexametasona/uso terapéutico , Implantes de Medicamentos , Estudios de Seguimiento , Glucocorticoides/uso terapéutico , Humanos , Inyecciones Intravítreas , Edema Macular/diagnóstico , Edema Macular/tratamiento farmacológico , Edema Macular/etiología , Estudios Retrospectivos , Uveítis/complicaciones , Uveítis/diagnóstico , Uveítis/tratamiento farmacológico , Uveítis Intermedia/complicaciones , Uveítis Intermedia/diagnóstico , Uveítis Intermedia/tratamiento farmacológicoAsunto(s)
Edema Macular , Uveítis Intermedia , Dexametasona/efectos adversos , Implantes de Medicamentos , Glucocorticoides/efectos adversos , Humanos , Inyecciones Intravítreas , Edema Macular/tratamiento farmacológico , Edema Macular/etiología , Estudios Retrospectivos , Tomografía de Coherencia Óptica , Uveítis Intermedia/diagnóstico , Uveítis Intermedia/tratamiento farmacológicoRESUMEN
TOPIC: The Collaborative Ocular Tuberculosis Study (COTS), supported by the International Ocular Inflammation Society, International Uveitis Study Group, and Foster Ocular Immunological Society, set up an international, expert-led consensus project to develop evidence- and experience-based guidelines for the management of tubercular uveitis (TBU). CLINICAL RELEVANCE: The absence of international agreement on the use of antitubercular therapy (ATT) in patients with TBU contributes to a significant heterogeneity in the approach to the management of this condition. METHODS: Consensus statements for the initiation of ATT in TBU were generated using a 2-step modified Delphi technique. In Delphi step 1, a smart web-based survey based on background evidence from published literature was prepared to collect the opinion of 81 international experts on the use of ATT in different clinical scenarios. The survey included 324 questions related to tubercular anterior uveitis (TAU), tubercular intermediate uveitis (TIU), tubercular panuveitis (TPU), and tubercular retinal vasculitis (TRV) administered by the experts, after which the COTS group met in November 2019 for a systematic and critical discussion of the statements in accordance with the second round of the modified Delphi process. RESULTS: Forty-four consensus statements on the initiation of ATT in TAU, TIU, TPU, and TRV were obtained, based on ocular phenotypes suggestive of TBU and corroborative evidence of tuberculosis, provided by several combinations of immunologic and radiologic test results. Experts agreed on initiating ATT in recurrent TAU, TIU, TPU, and active TRV depending on the TB endemicity. In the presence of positive results for any 1 of the immunologic tests along with radiologic features suggestive of past evidence of tuberculosis infection. In patients with a first episode of TAU, consensus to initiate ATT was reached only if both immunologic and radiologic test results were positive. DISCUSSION: The COTS consensus guidelines were generated based on the evidence from published literature, specialists' opinions, and logic construction to address the initiation of ATT in TBU. The guidelines also should inform public policy by adding specific types of TBU to the list of conditions that should be treated as tuberculosis.
Asunto(s)
Antituberculosos/uso terapéutico , Infecciones Bacterianas del Ojo/tratamiento farmacológico , Panuveítis/tratamiento farmacológico , Vasculitis Retiniana/tratamiento farmacológico , Tuberculosis Ocular/tratamiento farmacológico , Uveítis Anterior/tratamiento farmacológico , Uveítis Intermedia/tratamiento farmacológico , Algoritmos , Quimioterapia Adyuvante , Técnica Delphi , Infecciones Bacterianas del Ojo/diagnóstico , Infecciones Bacterianas del Ojo/microbiología , Glucocorticoides/uso terapéutico , Humanos , Ensayos de Liberación de Interferón gamma , Panuveítis/diagnóstico , Panuveítis/microbiología , Radiografía Torácica , Vasculitis Retiniana/microbiología , Estudios Retrospectivos , Encuestas y Cuestionarios , Tomografía Computarizada por Rayos X , Tuberculosis Ocular/diagnóstico , Tuberculosis Ocular/microbiología , Uveítis Anterior/diagnóstico , Uveítis Anterior/microbiología , Uveítis Intermedia/microbiologíaRESUMEN
PURPOSE: To evaluate long-term efficacy and safety of extended treatment with adalimumab in patients with noninfectious intermediate, posterior, or panuveitis. DESIGN: Open-label, multicenter, phase 3 extension study (VISUAL III). PARTICIPANTS: Adults who had completed a randomized, placebo-controlled phase 3 parent trial (VISUAL I or II) without treatment failure (inactive uveitis) or who discontinued the study after meeting treatment failure criteria (active uveitis). METHODS: Patients received subcutaneous adalimumab 40 mg every other week. Data were collected for ≤ 362 weeks. Adverse events (AEs) were recorded until 70 days after the last dose. MAIN OUTCOME MEASURES: Long-term safety and quiescence; other efficacy variables included inflammatory lesions, anterior chamber cell and vitreous haze grade, macular edema, visual acuity, and dose of uveitis-related systemic corticosteroids. RESULTS: At study entry, 67% of patients (283/424) showed active uveitis and 33% (141/424) showed inactive uveitis; 60 patients subsequently met exclusion criteria, and 364 were included in the intention-to-treat analysis. Efficacy variables were analyzed through week 150, when approximately 50% of patients (214/424) remained in the study. Patients showing quiescence increased from 34% (122/364) at week 0 to 85% (153/180) at week 150. Corticosteroid-free quiescence was achieved by 54% (66/123) and 89% (51/57) of patients with active or inactive uveitis at study entry. Mean daily dose of systemic corticosteroids was reduced from 9.4 ± 17.1 mg/day at week 0 (n = 359) to 1.5 ± 3.9 mg/day at week 150 (n = 181). The percentage of patients who achieved other efficacy variables increased over time for those with active uveitis at study entry and was maintained for those with inactive uveitis. The most frequently reported treatment-emergent AEs of special interest were infections (n = 275; 79 events/100 patient-years [PY]); AEs and serious AEs occurred at a rate of 396 events/100 PY and 15 events/100 PY, respectively. CONCLUSIONS: Long-term treatment with adalimumab led to quiescence and reduced corticosteroid use for patients who entered VISUAL III with active uveitis and led to maintenance of quiescence for those with inactive uveitis. AEs were comparable with those reported in the parent trials and consistent with the known safety profile of adalimumab.
Asunto(s)
Adalimumab/administración & dosificación , Panuveítis/tratamiento farmacológico , Uveítis Intermedia/tratamiento farmacológico , Uveítis Posterior/tratamiento farmacológico , Agudeza Visual , Adulto , Anciano , Anciano de 80 o más Años , Antiinflamatorios/administración & dosificación , Relación Dosis-Respuesta a Droga , Femenino , Estudios de Seguimiento , Humanos , Inyecciones Subcutáneas , Masculino , Persona de Mediana Edad , Panuveítis/diagnóstico , Estudios Retrospectivos , Factores de Tiempo , Resultado del Tratamiento , Uveítis Intermedia/diagnóstico , Uveítis Posterior/diagnóstico , Adulto JovenRESUMEN
PURPOSE: To evaluate long-term risk and outcomes of glaucoma in eyes with intermediate, posterior, and panuveitis managed with systemic or fluocinolone acetonide (0.59 mg, "implant") therapy. DESIGN: Prospective Follow-up of the Multicenter Uveitis Steroid Treatment (MUST) Clinical Trial Cohort. METHODS: Patients with intermediate, posterior, or panuveitis randomized to implant or systemic therapy (corticosteroid plus immunosuppression in >90%) were followed prospectively for glaucoma incidence and outcome. RESULTS: Among 405 uveitic at-risk eyes of 232 patients (median follow-up = 6.9 years), 40% (79/196) of eyes assigned and treated with implant and 8% (17/209) of eyes assigned and treated with systemic therapy (censoring eyes receiving an implant on implantation) developed glaucoma (hazard ratio [HR] = 5.9, 95% confidence interval [CI] 3.2, 10.8; P < .001). Adjustment for intraocular pressure (IOP) elevation during follow-up only partially mitigated the association of implant treatment with glaucoma incidence: HR = 3.1 (95% CI 1.6, 6.0); P = .001. Among 112 eyes of 83 patients developing glaucoma, the 5-year cumulative incidence following diagnosis of sustained (2 or more consecutive visits) worsening of mean deviation by ≥6 dB was 20% (95% CI 12%, 33%); 5-year cumulative incidence of sustained worsening of cup-to-disc ratio by ≥0.2 was 26% (95% CI 17%, 39%). CONCLUSIONS: The implant has substantially higher risk of glaucoma than systemic therapy, a difference not entirely explained by posttreatment IOP elevation. Management of IOP elevation was effective in preventing worsening of glaucoma for the large majority of cases, but even under expert clinical management, some glaucoma worsened. Uveitis cases should be monitored carefully for IOP elevation and glaucoma indefinitely.
Asunto(s)
Fluocinolona Acetonida/administración & dosificación , Glaucoma/epidemiología , Glucocorticoides/administración & dosificación , Panuveítis/complicaciones , Uveítis Intermedia/complicaciones , Uveítis Posterior/complicaciones , Adulto , Implantes de Medicamentos , Femenino , Estudios de Seguimiento , Glaucoma/fisiopatología , Humanos , Incidencia , Presión Intraocular/fisiología , Masculino , Persona de Mediana Edad , Panuveítis/tratamiento farmacológico , Estudios Prospectivos , Factores de Riesgo , Resultado del Tratamiento , Uveítis Intermedia/tratamiento farmacológico , Uveítis Posterior/tratamiento farmacológico , Agudeza Visual/fisiología , Cuerpo VítreoRESUMEN
OBJECTIVE: To compare the efficacy and safety of Disease-modifying antirheumatic drugs (DMARDs) and anti-TNF-α agents in patients with non-infectious non-anterior uveitis. METHODS: Single center retrospective study including adult patients with non-infectious intermediate, posterior or pan-uveitis. Outcomes were compared between patients treated with DMARDs or anti-TNF-α agents. The primary outcome was treatment failure or occurrence of serious adverse events. Treatment failure was determined by ophthalmologic criteria. RESULTS: Seventy-three patients were included, mostly female (52%). Among them, 39 were treated with DMARDs and 34 with anti-TNF-α agents. The main uveitis causes were idiopathic (30%), birdshot chorio-retinopathy (25%), sarcoidosis (16%) and Behçet's disease (14%). The primary outcome was observed in 56% of patients treated with anti-TNF-α agents versus 59% of patients treated with DMARDs (p = 0.82). Median time to observe the primary outcome was 16 months (anti-TNF-α group) versus 21 months (p = 0.52). There was no significant difference between the two groups in terms of treatment failure, corticosteroid sparing effect, visual acuity improvement or adverse events. Earlier control of ocular inflammation was achieved with anti-TNF-α agents than with DMARDs (p = 0.006). In relapsing patients, anti-TNF-α agents allowed better corticosteroid sparing (p = 0.06). CONCLUSION: DMARDs could still be used as first-line therapy for non-infectious non-anterior uveitis after corticosteroid therapy. However, anti-TNF-α agents could be proposed as an alternative in cases of severe inflammation or initial high level of steroid dependency.
Asunto(s)
Antirreumáticos/administración & dosificación , Inmunosupresores/administración & dosificación , Panuveítis/tratamiento farmacológico , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Uveítis Intermedia/tratamiento farmacológico , Adalimumab/administración & dosificación , Adalimumab/efectos adversos , Adulto , Antirreumáticos/efectos adversos , Femenino , Estudios de Seguimiento , Humanos , Inmunosupresores/efectos adversos , Infliximab/administración & dosificación , Infliximab/efectos adversos , Masculino , Persona de Mediana Edad , Panuveítis/diagnóstico , Panuveítis/inmunología , Recurrencia , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Uveítis Intermedia/diagnóstico , Uveítis Intermedia/inmunología , Agudeza VisualRESUMEN
Intermediate uveitis is a rare disease. Interdiscliplinary investigations to identify or exclude an associated systemic disease (in Central Europe, this would primarily mean sarcoidosis and multiple sclerosis) should be initiated even at the first manifestation of disease. Therapy should be started in those patients with marked inflammatory activity or secondary complications and primarily encompasses local and systemic corticosteroids, although some patients need second line steroid sparing systemic DMARD therapy (DMARD: disease-modifying antirheumatic drug).
Asunto(s)
Antirreumáticos/uso terapéutico , Esclerosis Múltiple , Sarcoidosis , Uveítis Intermedia/tratamiento farmacológico , Uveítis/tratamiento farmacológico , Adulto , Niño , Europa (Continente) , HumanosRESUMEN
PURPOSE: To determine the time to disease recurrence with long-acting injectable fluocinolone acetonide implant (FAi) for noninfectious intermediate, posterior, and panuveitis. METHODS: This was a retrospective study of patients with at least 12 months of follow-up who had completed a 2-year prospective, investigational new drug study with 0.18-mg FAi. Time to uveitis recurrence or cystoid macular edema (CME) occurrence was recorded. RESULTS: Twelve eyes from 12 participants (mean age 43 years, range 25-64 years) were included. Patients were followed for a mean of 34.2 months (range, 12.0-56.9 months) after completion of the prospective trial. Five eyes (42%) did not have a documented uveitis recurrence or CME occurrence. Five eyes (42%) had a uveitis recurrence with the mean time to recurrence 36.1 months (range, 22.8-61.1 months) after FAi implantation. Two eyes (16%) had CME alone, the mean time to occurrence 36.9 months (range 36.1-42.1 months). On Kaplan-Meier analysis, the estimated probability of remaining recurrence-free 36 months after FAi implantation was 0.67 (95% confidence interval, 0.34-0.86). CONCLUSIONS: Data of study participants after completing a clinical trial suggest that the injectable FAi for noninfectious uveitis can provide control for 3 years on average. These long-term data support the use of FAi to control noninfectious uveitis.
Asunto(s)
Fluocinolona Acetonida/administración & dosificación , Glucocorticoides/administración & dosificación , Panuveítis/diagnóstico , Uveítis Intermedia/diagnóstico , Uveítis Posterior/diagnóstico , Adulto , Implantes de Medicamentos , Femenino , Estudios de Seguimiento , Humanos , Presión Intraocular/fisiología , Edema Macular/diagnóstico , Edema Macular/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Panuveítis/tratamiento farmacológico , Recurrencia , Estudios Retrospectivos , Factores de Tiempo , Tomografía de Coherencia Óptica , Uveítis Intermedia/tratamiento farmacológico , Uveítis Posterior/tratamiento farmacológico , Agudeza Visual/fisiologíaRESUMEN
PURPOSE OF REVIEW: Local therapeutics play an important role in the management of infectious and noninfectious uveitis (NIU) as well as certain masquerade syndromes. This review highlights the established therapeutics and those under investigation for the management of uveitis. RECENT FINDINGS: An injectable long-acting fluocinolone acetonide insert was recently approved by the Food and Drug Administration for the treatment of NIU affecting the posterior segment. Intravitreal methotrexate, sirolimus, and anti-vascular endothelial growth factor (VEGF) agents are being evaluated for efficacy in NIU. Intravitreal foscarnet and ganciclovir are important adjuncts in the treatment of viral retinitis as are methotrexate and rituximab for the management of vitreoretinal lymphoma. SUMMARY: Local injectable steroids with greater durability are now available for NIU but comparative efficacy to other treatment modalities remains to be determined. Local steroid-sparing immunosuppressive agents are undergoing evaluation for efficacy in NIU as are anti-VEGF agents for uveitic macular edema. Local antivirals may improve outcomes in cases of viral retinitis. Local chemotherapeutics can help induce remission in vitreoretinal lymphoma.